Phase 3
N=42
Dexamethasone for Post Uterine Artery Embolization Pain
Leiomyoma
Bottom Line
View on ClinicalTrials.gov: NCT04655144 ↗Enrolled (actual)
42
Serious AEs
0.0%
Results posted
Sep 2025
Primary outcome: Primary: Pain Scores Using the VAS Questionnaire — 0.8; 1.3; 4; 6.1 score on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- Dexamethasone (Drug); Saline (Drug)
- Age
- Adult · 20+ yrs
- Sex
- Female
- Sponsor
- University of Miami
- Primary completion
- Dec 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Pain Scores Using the VAS Questionnaire |
0.8; 1.3; 4; 6.1; 6; 6.3 | — |
| SECONDARY Severity of Post-embolization Syndrome Symptoms |
0; 0; 0.1; 0.2; 0.3; 0.4 | — |
| SECONDARY Change in Symptoms |
2.4; 2.3; 1.7; 1.8; 1.9; 1.9 | — |
| SECONDARY Change in Quality of Life |
5.2; 5.5; 2.5; 1.3 | — |
Summary
The purpose of this research is to investigate if administration steroids (anti-inflammatory medication) via the uterine arteries during uterine fibroid embolization (A non surgical procedure for treating uterine fibroids by blocking their blood supply) can help reduce the pain, nausea, vomiting, and general feeling of weakness following the procedure.
Eligibility Criteria
Inclusion Criteria
- Women who meet criteria to undergo uterine fibroid embolization for symptomatic fibroids.
Exclusion Criteria
- Currently pregnant or actively attempting to conceive
- Those deemed mentally impaired to make their own medical decisions
- Previous documented allergy to dexamethasone
- Those currently taking daily steroids for any reason
- Those with diabetes or deemed to be pre-diabetic
- Those with contraindications for angiography
- Prisoners
Data sourced from ClinicalTrials.gov (NCT04655144). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.